Roth Adds Achillion Pharma (ACHN) to 'Focus List'
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Price: $0.79 --0%
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 6
Rating Summary:
11 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 6
Join SI Premium – FREE
Following news of preliminary Phase 1b proof-of-concept data on the company's ACH-2928 NS5A inhibitor this morning, an analyst at Roth Capital added shares of Achillion Pharma (Nasdaq: ACHN) to the firm's "Focus List" Monday morning.
The stock is up more than 2 percent to $7.01 at last check.
Roth's David Moskowitz maintains a Buy rating and $10 price target on shares of Achillion.
The stock is up more than 2 percent to $7.01 at last check.
Roth's David Moskowitz maintains a Buy rating and $10 price target on shares of Achillion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aptevo raises $4.5M through warrant exercise and private placement
- Truist Securities Reiterates Buy Rating on Arrow Electronics (ARW)
- UBS Starts Nuvama Wealth Management (NUVAMA:IN) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Corporate NewsRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
